Testing a Mobile App to Guide Insulin Dosing in Diabetes
Tests a phone app for insulin dosing in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol
Key facts
- Where
- Madrid and Toledo, SpainSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07304778, who can take part
Where in Spain
- Universidad Complutense de MadridMadrid, SpainNot yet recruiting
- Hospital Universitario de ToledoToledo, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidad Complutense de Madrid
- Trial code
- NCT07304778
- Record updated
- 6 January 2026
- Original description
The goal of this clinical trial is to evaluate the safety and efficacy of integrating predictive models into insulin therapy management via the user-centered glUCModel mobile app in People with Type 1 Diabetes Mellitus following Multiple Insulin Dosing therapy. Participants will be aged 18 to 65 years. The main questions it aims to answer are:Read full original descriptionShow less
Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol
The goal of this clinical trial is to evaluate the safety and efficacy of integrating predictive models into insulin therapy management via the user-centered glUCModel mobile app in People with Type 1 Diabetes Mellitus following Multiple Insulin Dosing therapy. Participants will be aged 18 to 65 years. The main questions it aims to answer are:
Does using the app improve glycaemic control, as measured by time in range? Does using the app reduce the number of episodes of hyperglycaemia and hypoglycaemia? Are the app's design and functionality adequate?
The study will comprise four phases:ses}):
* Screening phase: Informed consent, collection of sociodemographic and clinical data, and baseline Pittsburg, IFIS, and DTSQ questionnaires. * Run-in phase: 2 weeks of standard care with CGM. Data will be used to generate personalized predictive models in the intervention group. * Active treatment phase: Participants continue MDI therapy. The intervention group will additionally use the glUCModel mobile app. CGM data from the final 2 weeks will be analyzed. * Evaluation and analysis phase: Participants will complete the uMARS, Pittsburgh, and DTSQ questionnaires. Statistical analysis and correlations among outcomes will be processed.
Inclusion: HbA1c < 9%; Currently following an MDI Bolus-Basal therapy; Wearing CGMs connected to a mobile phone; Spanish language proficiency; Willingness to participate in the trial; At least one year since the time of diabetes diagnosis; Ability to use a mobile application like glUCModel; Own a mobile phone running Android or iOS operating system; Ability to follow a Portion-controlled diet for diabetes; Educated to do an active management of insulin dosing.
Exclusion: Subjects in treatment with corticoids; Patients who have required hospitalization or surgery in the last six months; Less than one year since the time of diabetes diagnosis; Unable to follow a Portion-controlled diet for diabetes; Diagnosed with a significant psychiatric disorder; HbA1c < 9%; Not wearing CGMs; Non-Spanish language proficiency; Unable to use a mobile application like glUCModel; Unable to do an active management of insulin dosing; Pregnancy or planning a pregnancy.